This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by La Seta Catamancio, S. Articles by Rusconi, S. Search for Related Content PubMed PubMed Citation Articles by La Seta Catamancio, S. Articles by Rusconi, S.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, March 2001, p. 1124-1129, Vol. 39, No. 3
0095-1137/01/$04.00+0   DOI: 10.1128/JCM.39.3.1124-1129.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

In Vitro Evolution of the Human Immunodeficiency Virus Type 1 Gag-Protease Region and Maintenance of Reverse Transcriptase Resistance following Prolonged Drug Exposure

Simona La Seta Catamancio, Maria Pia De Pasquale, Paola Citterio, Semir Kurtagic, Massimo Galli, and Stefano Rusconi^*

Istituto di Malattie Infettive e Tropicali, Università di Milano, Ospedale Luigi Sacco, Milan, Italy

Received 21 April 2000/Returned for modification 24 August 2000/Accepted 15 December 2000

We studied the human immunodeficiency virus type 1 phenotypic and genotypic profiles of a dual drug-resistant isolate (isolate 14aPost-DR) selected for zidovudine (ZDV) and lamivudine (3TC) resistance and then cultured in the presence of 3TC and a protease inhibitor: indinavir (IDV), ritonavir, or KNI-272. The IDV-treated virus was highly resistant to 3TC, ZDV, and IDV and accumulated protease mutations at positions M46I and V82F. A change from alanine to valine was observed in 4 of 10 clones in the P2 position of the p7-p1 Gag-protease cleavage site, linked to position M46I in the dominant viral quasispecies. Previous 3TC resistance did not impair the development of additional mutations in the protease and Gag-protease cleavage regions.

---

^* Corresponding author. Mailing address: Istituto di Malattie Infettive e Tropicali, Università di Milano, Ospedale Luigi Sacco, via GB Grassi 74, 20157 Milan, Italy. Phone: 011.39.02.39043350. Fax: 011.39.02.3560805. E-mail: rusconi{at}mailserver.unimi.it.

This report is dedicated to the memory of Alessandro Caporali.

Present address: Infectious Disease Unit, Massachusetts General Hospital-East, Charlestown, MA 02129.

---

Journal of Clinical Microbiology, March 2001, p. 1124-1129, Vol. 39, No. 3
0095-1137/01/$04.00+0   DOI: 10.1128/JCM.39.3.1124-1129.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

This article has been cited by other articles:

• Prabu-Jeyabalan, M., Nalivaika, E. A., Romano, K., Schiffer, C. A. (2006). Mechanism of substrate recognition by drug-resistant human immunodeficiency virus type 1 protease variants revealed by a novel structural intermediate.. J. Virol. 80: 3607-3616 [Abstract] [Full Text]  
• Prabu-Jeyabalan, M., Nalivaika, E. A., King, N. M., Schiffer, C. A. (2004). Structural Basis for Coevolution of a Human Immunodeficiency Virus Type 1 Nucleocapsid-p1 Cleavage Site with a V82A Drug-Resistant Mutation in Viral Protease. J. Virol. 78: 12446-12454 [Abstract] [Full Text]  
• King, N. M., Prabu-Jeyabalan, M., Nalivaika, E. A., Wigerinck, P., de Bethune, M.-P., Schiffer, C. A. (2004). Structural and Thermodynamic Basis for the Binding of TMC114, a Next-Generation Human Immunodeficiency Virus Type 1 Protease Inhibitor. J. Virol. 78: 12012-12021 [Abstract] [Full Text]  
• Rusconi, S., Bulgheroni, E., La Seta Catamancio, S., Croce, F., Cicero, M. L., Citterio, P., Galli, M. (2002). Accumulation of drug-related mutations in HIV-1 genome and virus replicative capacity in multi-drug failure subjects. J Antimicrob Chemother 49: 427-429 [Full Text]